SEC
GPCR icon

Seven Eight Capital’s Structure Therapeutics GPCR Stock Holding History

Seven Eight Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,337
Closed -$1.35M – 806
2024
Q2 		$1.35M Buy
+34,337
New +$1.41M 0.14% 248

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Seven Eight Capital's GPCR Position: Q3 2024 in Review

Seven Eight Capital sold out of Structure Therapeutics (GPCR) in Q3 2024, closing a stake of 34,337 shares — an estimated $1.35M sold.

Seven Eight Capital first reported a position in GPCR in Q2 2024 and held it in 1 quarter. The position peaked at $1.35M in Q2 2024. 160 funds tracked by Wall St. Rank hold GPCR as of Q3 2024.

  • Seven Eight Capital reported no remaining Structure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 34,337 Structure Therapeutics shares in Q3 2024, an estimated $1.35M.
  • Seven Eight Capital first reported a position in Structure Therapeutics in Q2 2024 and held it in 1 quarter.
  • Seven Eight Capital's Structure Therapeutics position peaked at $1.35M in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.